{"schema_version":"secwatch.filing_event.v1","accession":"0001438533-23-000018","form_type":"8-K","ticker":"TVTX","cik":"0001438533","company_name":"Travere Therapeutics, Inc.","filed_at":"2023-05-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.876500+00:00","generated_at":"2026-06-16T04:50:32.668453+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Travere's sparsentan misses primary eGFR endpoint in Phase 3 FSGS study; proteinuria trends favorable","bullets":["eGFR total slope difference 0.3 mL/min/1.73m2/yr favoring sparsentan (p=0.7491), not statistically significant.","eGFR chronic slope difference 0.9 mL/min/1.73m2/yr (p=0.4203), also not significant.","Proteinuria reduced 50% with sparsentan vs 32% with irbesartan at week 108; FPRE 38% vs 23%.","Company plans to engage FDA and EMA to explore potential path for regulatory submission.","Sparsentan well-tolerated with safety profile comparable to irbesartan through 108 weeks."],"urls":{"canonical":"https://secwatch.observer/filing/0001438533-23-000018","json":"https://secwatch.observer/filing/0001438533-23-000018.json","markdown":"https://secwatch.observer/filing/0001438533-23-000018.md","text":"https://secwatch.observer/filing/0001438533-23-000018.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1438533/000143853323000018/0001438533-23-000018-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1438533/000143853323000018/tvtx-20230501.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T04:50:32.668453+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}